Order Summary

For New Jersey Subscribers​ For Other Subscribers​
Price: $5,000​.00 Price: $5.000​.00
Tax: 7%​​​​ Tax: NA​​​​

[accept_stripe_payment name="Specialty Ingredients and Excipients for Biologics: Impact of COVID-19 on the Global Market" price="5000" tax="7" url="https://www.klinegroup.com/wp-content/uploads/Y8611-Covid-19-Biologics-brochure.pdf" thankyou_page_url="https://klinegroup.com/market-research/e-comm-thank-you-for-purchase/" description="Specialty Ingredients and Excipients for Biologics: Impact of COVID-19 on the Global Market" button_text="Pay $5,350.00"]

[accept_stripe_payment name="Specialty Ingredients and Excipients for Biologics: Impact of COVID-19 on the Global Market" price="5000" url="https://www.klinegroup.com/wp-content/uploads/Y8611-Covid-19-Biologics-brochure.pdf" thankyou_page_url="https://klinegroup.com/market-research/e-comm-thank-you-for-purchase/" description="Specialty Ingredients and Excipients for Biologics: Impact of COVID-19 on the Global Market" button_text="Pay $5,000.00"]

Specialty Ingredients and Excipients for Biologics: Impact of COVID-19 on the Global Market

Download Brochure

A special report on the impact of COVID-19 on the global market of specialty chemicals in biologic pharmaceuticals, with forecasts for different scenarios that the industry is likely to face.

 

Scope:

  • A comprehensive analysis of global biopharmaceuticals industry developments and their impact on demand for specialty chemicals in different stages of production, including:
    • — Upstream Manufacturing
      • — Classic cell culture media, Cell Expression Systems, Cell Culture Ingredients and Supplements, and Buffers
    • — Downstream Processing
      • — Stabilizers, Surfactants, Salts, Antioxidants, and Buffers
    • — Final Formulation
      • — Stabilizers and Bulking Agents, Surfactants, Salts, Antioxidants, Buffers, Vaccine Adjuvants, and Chelating Agents
  • This report analyzes four key scenarios of development:
    • — CASE 1: mAbs as a cure
    • — CASE 2: Vaccine developed
    • — CASE 3: Success in Recombinant Technology
    • — CASE 4: Small-Molecule Drugs as Winners